questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Gènes régulateurs
Gènes switch
Gènes switch : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes switch : Questions médicales les plus fréquentes",
"headline": "Gènes switch : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes switch : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-19",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes switch"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gènes régulateurs",
"url": "https://questionsmedicales.fr/mesh/D005809",
"about": {
"@type": "MedicalCondition",
"name": "Gènes régulateurs",
"code": {
"@type": "MedicalCode",
"code": "D005809",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.425"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes switch",
"alternateName": "Genes, Switch",
"code": {
"@type": "MedicalCode",
"code": "D005812",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Martin Fussenegger",
"url": "https://questionsmedicales.fr/author/Martin%20Fussenegger",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland; University of Basel, Faculty of Life Science, Basel, Switzerland. Electronic address: fussenegger@bsse.ethz.ch."
}
},
{
"@type": "Person",
"name": "Ana Palma Teixeira",
"url": "https://questionsmedicales.fr/author/Ana%20Palma%20Teixeira",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland."
}
},
{
"@type": "Person",
"name": "Jin Wang",
"url": "https://questionsmedicales.fr/author/Jin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Physics and Applied Mathematics, State University of New York at Stony Brook, Stony Brook, New York 11794, USA."
}
},
{
"@type": "Person",
"name": "Jörg S Hartig",
"url": "https://questionsmedicales.fr/author/J%C3%B6rg%20S%20Hartig",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany; Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany. Electronic address: joerg.hartig@uni-konstanz.de."
}
},
{
"@type": "Person",
"name": "Omer Gokcumen",
"url": "https://questionsmedicales.fr/author/Omer%20Gokcumen",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Complement.",
"datePublished": "2023-08-08",
"url": "https://questionsmedicales.fr/article/37551641",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42671"
}
},
{
"@type": "ScholarlyArticle",
"name": "Complement component 3 and complement factor H protein levels are altered in brain tissues from people with human immunodeficiency virus: A pilot study.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36118688",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fnagi.2022.981937"
}
},
{
"@type": "ScholarlyArticle",
"name": "Truncated Complement Factor H Y402 Gene Therapy Cures C3 Glomerulonephritis.",
"datePublished": "2024-09-21",
"url": "https://questionsmedicales.fr/article/39345485",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/2024.09.17.613471"
}
},
{
"@type": "ScholarlyArticle",
"name": "Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37376642",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v15061343"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical Significance and Potential Function of Complement Factor D in Acute Myeloid Leukemia.",
"datePublished": "2024-08-20",
"url": "https://questionsmedicales.fr/article/39310420",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.67260"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes régulateurs",
"item": "https://questionsmedicales.fr/mesh/D005809"
},
{
"@type": "ListItem",
"position": 8,
"name": "Gènes switch",
"item": "https://questionsmedicales.fr/mesh/D005812"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes switch - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes switch",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes switch",
"description": "Comment identifier un gène switch ?\nQuels tests sont utilisés pour les gènes switch ?\nLes gènes switch sont-ils visibles sur une analyse génétique ?\nPeut-on détecter des mutations dans les gènes switch ?\nQuels marqueurs sont associés aux gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes switch",
"description": "Quels symptômes sont liés aux gènes switch ?\nLes gènes switch affectent-ils le développement ?\nPeut-on observer des anomalies dues aux gènes switch ?\nLes gènes switch influencent-ils le comportement ?\nY a-t-il des symptômes neurologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes switch",
"description": "Peut-on prévenir les maladies liées aux gènes switch ?\nQuels modes de vie peuvent aider à prévenir ces maladies ?\nLes conseils génétiques sont-ils utiles ?\nY a-t-il des vaccins pour prévenir les effets des gènes switch ?\nComment le suivi médical contribue-t-il à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes switch",
"description": "Comment traiter les dysfonctionnements des gènes switch ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques pour ces traitements ?\nLes traitements sont-ils efficaces ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes switch",
"description": "Quelles complications peuvent survenir avec les gènes switch ?\nLes gènes switch peuvent-ils causer des maladies héréditaires ?\nY a-t-il des risques de transmission familiale ?\nLes complications sont-elles réversibles ?\nComment les gènes switch affectent-ils la longévité ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes switch",
"description": "Quels facteurs de risque sont associés aux gènes switch ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il les gènes switch ?\nLes facteurs génétiques jouent-ils un rôle ?\nLes infections peuvent-elles affecter les gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un gène switch ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme le séquençage et l'analyse d'expression génique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes switch ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de PCR et des analyses de microarray sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les gènes switch sont-ils visibles sur une analyse génétique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être détectés indirectement par l'expression des gènes qu'ils régulent."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les gènes switch ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations peuvent être identifiées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux gènes switch ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs épigénétiques comme les méthylations peuvent indiquer leur activité."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux gènes switch ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon les gènes régulés, incluant des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les gènes switch affectent-ils le développement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils jouent un rôle crucial dans le développement embryonnaire et cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies dues aux gènes switch ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent se manifester par des malformations congénitales ou des cancers."
}
},
{
"@type": "Question",
"name": "Les gènes switch influencent-ils le comportement ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch peuvent affecter des traits comportementaux et cognitifs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines dysrégulations peuvent entraîner des troubles neurologiques variés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux gènes switch ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par le dépistage génétique et des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels modes de vie peuvent aider à prévenir ces maladies ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est bénéfique."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques aident à évaluer les risques et à planifier des actions préventives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir les effets des gènes switch ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical contribue-t-il à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet de détecter précocement des anomalies et d'intervenir rapidement."
}
},
{
"@type": "Question",
"name": "Comment traiter les dysfonctionnements des gènes switch ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblés peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques pour ces traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux essais cliniques explorent des thérapies pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de gène switch et la pathologie associée."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent inclure des réactions immunitaires ou des complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les gènes switch ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et des malformations."
}
},
{
"@type": "Question",
"name": "Les gènes switch peuvent-ils causer des maladies héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch sont impliqués dans des maladies héréditaires complexes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de transmission familiale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les gènes switch peuvent être transmis et affecter plusieurs membres d'une famille."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Comment les gènes switch affectent-ils la longévité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements peuvent réduire l'espérance de vie en augmentant le risque de maladies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux gènes switch ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs environnementaux, génétiques et comportementaux peuvent influencer leur activité."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter l'expression des gènes switch et le risque de maladies."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les gènes switch ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme ou l'alimentation peuvent moduler leur activité."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent prédisposer à des dysfonctionnements des gènes switch."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter les gènes switch ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent altérer l'expression des gènes switch et provoquer des maladies."
}
}
]
}
]
}
The role of complement in human autoimmune, inflammatory, and infectious diseases is reviewed, focusing on clinical applicability. A typical case is presented in which serum testing for C3 and C4 is p...
People with HIV (PWH) continue to suffer from dysfunction of the central nervous system, as evidenced by HIV-associated neurocognitive disorder (HAND), despite antiretroviral therapy and suppressed vi...
Patients with both age-related macular degeneration (AMD) and C3 glomerulonephritis (C3G) are challenged by the absence of effective therapies to reverse and eliminate their disease burden. Capitalizi...
Adenovirus has strong therapeutic potential as an oncolytic virus and gene therapy vector. However, injecting human species C serotype 5 adenovirus, HAdv-C5, into the bloodstream leads to numerous int...
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by aggressive proliferation and a poor prognosis. The objective of this study is to elucidate the specific role of complement fac...
We performed a systematic investigation on clinical significance and potential function of CFD in AML by using the R Programming Language with The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (...
The expression of CFD was the highest in AML cells than in other tumor cell lines. The expression of CFD was also higher in AML patients than in the matched normal group. Compared with the low express...
CFD could serve as a potential OS prognostic biomarker and guide clinical treatment for AML....
The tumor immune microenvironment is distinct between early-onset and late-onset colorectal cancer which facilitates tumor progression. We previously identified several genes, including complement fac...
This study aimed to assess and validate differential expression of immune genes in early and late-onset colorectal cancer. We also aimed to test known drugs targeting genes increased in early-onset co...
Retrospective cohort study with analysis performed using tumor RNA from formalin-fixed paraffin-embedded, cell culture and immunohistochemistry to validate gene expression and gene function. In vivo p...
Oregon Colorectal Cancer Registry was queried to find patients with colorectal cancer....
Study included 67 patients with early and 54 patients with late-onset colorectal cancer....
Preclinical animal models using the HCT-116 colon cancer cell line were treated with complement factor D inhibitor danicopan and BCL2 inhibitor venetoclax, or with vehicle controls....
Elevated RNA signatures using NanoString data was evaluated from the retrospective cohort. When inhibiting these markers in the mouse preclinical model, tumor volume and weight were the main outcome m...
After updating our sample size from our previously published data, we found that complement factor D and BCL2, genes with known function and small molecule inhibitors, are elevated in patients with ea...
This study is limited by small sample size and a subcutaneous tumor model....
Combinatorial inhibition of early-onset associated genes complement factor D and BCL2 slows growth of early-onset colorectal cancer in a mouse preclinical model. See Video Abstract....
There are increasing investigations about the potential role of the complement system in disorders affecting the central nervous system, including schizophrenia. Therefore, we aim to evaluate the leve...
This cross-sectional study was conducted between January 2020 and January 2021 and included schizophrenia patients resistant to treatment or in remission and healthy controls. The Structured Clinical ...
In the treatment-resistant schizophrenia group, complement 3 (...
In light of the analyses, it can be said that complement concentration increases in certain stages of schizophrenia, and its imbalance may be associated with symptom severity and treatment resistance....
The deposition of pathological α-synuclein (α-Syn) in the central nervous system (CNS) is a hallmark of Parkinson's disease (PD). Notably, pathological α-Syn exists not only in the CNS but also in per...
Evidence of crosstalk between the complement and coagulation cascades exists, and dysregulation of either pathway can lead to serious thromboinflammatory events. Both the intrinsic pathway of coagulat...
The aim was to investigate crosstalk between FP and the intrinsic pathway and the potential downstream consequences....
Chromogenic assays were established to characterize autoactivation of FXI in the presence of dextran sulfate (DXS), enzyme kinetics of FXIa, and the downstream effects of FP on intrinsic pathway activ...
We identified a novel interaction of FP with FXIa resulting in functional consequences. FP reduces activity of autoactivated FXIa toward S-2288. FXIa can cleave FP in the presence of DXS, demonstrated...
The poor remodeling of placental spiral arteries seen in preeclampsia is also discussed to contribute to recurrent pregnancy loss (RPL) preceded by abnormal angiogenesis and excessive complement activ...